OGN
Organon & Co.
11.33
USD
This page is just a preview of the data found in TrendSpider’s full version
Organon & Co. stock is down -8.7% since 30 days ago. The next earnings date is Feb 15, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 100% of the previous 2 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 8 PUTs, 2 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 13 Nov 17:54 | 16 Jan, 2026 | 5.00 | 14 | ||
| 15 Nov 14:38 | 19 Jan, 2024 | 17.50 | 4112 | ||
| 15 Nov 14:38 | 20 Dec, 2024 | 17.50 | 77 | ||
| 15 Nov 16:14 | 16 Jan, 2026 | 12.50 | 149 | ||
| 17 Nov 16:59 | 19 Apr, 2024 | 12.50 | 880 | ||
| 20 Nov 19:33 | 19 Apr, 2024 | 12.50 | 951 | ||
| 24 Nov 14:43 | 19 Apr, 2024 | 10.00 | 7061 | ||
| 01 Dec 18:49 | 16 Jan, 2026 | 7.50 | 662 | ||
| 06 Dec 20:11 | 20 Dec, 2024 | 25.00 | 0 | ||
| 06 Dec 20:51 | 17 Jan, 2025 | 10.00 | 303 |
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies.
